FDA Grants Premarket Clearance of Asuragen’s AmplideX® Fragile X Dx and Carrier Screen Kit
Our AmplideX® Fragile X Dx and Carrier Screen Kit has been cleared by the United States Food and Drug Administration (FDA), making it the first and only test for the detection and quantification of expanded pathogenic repeat sequences to be cleared by the FDA.
Asuragen Expands Genetic Portfolio with Launch of AmplideX® PCR/CE HTT Kit
The AmplideX® PCR/CE HTT Kit is a simple, robust, and reliable test for the detection of CAG trinucleotide repeats within the HTT gene, aberrations which are associated with the development of Huntington’s Disease (HD).
The ACMG Annual Clinical Genetics Meeting provides genetics professionals with a high caliber scientific program that presents the latest developments and research in clinical genetics and genomics. Check back closer to the date of the show for more information regarding what we have planned!
Learn more about about the conference: https://www.acmgmeeting.net/acmg2020/
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.